Penumbra

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. Its target markets include interventional neuroradiologists, neurosurgeons, neurologists, cardiologists, radiologists, and vascular surgeons. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Penumbra reports robust Q2 earnings, eyes growth amidst challenges

Penumbra's Q2 2024 earnings call showcased strong financial performance, operational efficiency, and a commitment to innovation and market access initiatives.
While facing challenges in revenue guidance reduction and competitive dynamics, the company's strengths in product performance and growth prospects position it well for the future.
Opportunities exist in leveraging innovation, addressing market challenges, and optimizing margins to drive sustained growth and competitiveness in the industry.

Penumbra reports strong Q3 earnings, eyes global blood clot market

Penumbra's Q3 2024 earnings call showcased robust financial performance, driven by revenue growth and margin expansion. The company's innovative technologies and regulatory milestones position it for future success in the blood clot treatment market. While facing challenges in sustaining growth and navigating market dynamics, Penumbra has opportunities to capitalize on its strengths and drive global transformation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

Penumbra (PEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Penumbra (PEN) Surges 3.6%: Is This an Indication of Further Gains?

ALAMEDA, Calif. , July 7, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2022 after market close on Thursday, August 4, 2022 at 4:30 PM Eastern Time.

Penumbra, Inc. Schedules Second Quarter 2022 Earnings Release and Conference Call for August 4, 2022

We think that Penumbra (NYSE: PEN), a medical devices company focused on interventional therapies, currently is a better pick compared to the Gap stock (NYSE: GPS), a specialty retailer selling casual apparel, accessories, and personal care products, despite it being the more expensive of the two.

Strong Revenue Trends And Better Prospects Make Penumbra Stock A Good Bet

Penumbra Inc (NYSE: PEN) reported Q1 sales that beat Street expectations, driven by Vascular upside, and reiterated its 2022 revenue guidance.  Wells Fargo lowered the price target to $265 from 321, which is equivalent to a 52.2% upside.

Despite Seeing Accelerated 2023 Growth, This Analyst Cut Penumbra's Price Target - Here's Why

Penumbra, Inc. (NYSE:PEN ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Jee Hamlyn-Harris – Investor Relations Adam Elsesser – Chairman and Chief Executive Officer Maggie Yuen – Chief Financial Officer Jason Mills – Executive Vice President-Strategy Conference Call Participants Larry Biegelsen – Wells Fargo Robbie Marcus – JPMorgan Joanne Wuensch – Citi David Rescott – Truist Securities Ryan Zimmerman – BTIG Mike Matson – Needham & Company Pito Chickering – Deutsche Bank Operator Hello, my name is Stephanie and I'll be your conference operator today. At this time, I would like to welcome everyone to the Penumbra, Inc. First Quarter 2022 Earnings Conference Call.

Penumbra's (PEN) CEO Adam Elsesser on Q1 2022 Results - Earnings Call Transcript

Penumbra (PEN) delivered earnings and revenue surprises of -116.67% and 4.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Reports Q1 Loss, Tops Revenue Estimates

ALAMEDA, Calif. , May 3, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2022.

Penumbra, Inc. Reports First Quarter 2022 Financial Results

ALAMEDA, Calif. , April 26, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10, 2022.

Penumbra, Inc. to Present at the Bank of America Securities 2022 Healthcare Conference

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra, Inc.'s Indigo Aspiration System with Lightning 7 and Lightning 12 have secured CE Mark and are now commercially available in Europe.

Penumbra Announces the European Launch of the Indigo® System With Lightning™ 7 and Lightning 12 Intelligent Aspiration

ALAMEDA, Calif. , April 5, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2022 after market close on Tuesday, May 3, 2022 at 4:30 PM Eastern Time.

Penumbra, Inc. Schedules First Quarter 2022 Earnings Release and Conference Call for May 3, 2022

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra, Inc. introduces the REAL® Immersive System y-Series™ with significantly more activities and experiences.

Penumbra Introduces Next Generation REAL® y-Series™, Expanding Virtual Reality Healthcare Platform

ALAMEDA, Calif. , March 28, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022.

Penumbra, Inc. to Present at the 21st Annual Needham Virtual Healthcare Conference

Clover Health Investments

Vir Biotechnology

Looking for small healthcare companies with huge revenue opportunities? Try these.

These 3 Stocks Aren't Large Caps Yet, but They Each Could Make $1 Billion in Sales in 2022

The stock price of Penumbra, a medical devices company focused on interventional therapies, has seen a 16% fall in a month, while it was down 10% last week. The company reported mixed Q4 results last month, with revenue of $204 million and adjusted EPS of $0.10 per share, compared to the consensus.

Down 16% In A Month, Will Penumbra Stock Rebound?

Penumbra has been posting strong revenue growth numbers, but the Street has not been rewarding the shares.

Penumbra A Little Beaten Down Despite Strong Growth Opportunities

Penumbra Inc (NYSE: PEN) posted Q4 FY21 revenue of $204 million, +22.2% Y/Y (up 23% in constant currency), beating the consensus of $194.30 million. Revenue from sales of vascular products grew 30.4% (31.1%) to $113.6 million.

Penumbra Posts Mixed Bag Q4 Results, Reports Topline Growth Of 22%

The average of price targets set by Wall Street analysts indicates a potential upside of 40.2% in Penumbra (PEN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Penumbra (PEN) Could Rally 40%: Here's is How to Trade

Penumbra, Inc. (PEN) CEO Adam Elsesser on Q4 2021 Results - Earnings Call Transcript

Penumbra (PEN) delivered earnings and revenue surprises of -47.37% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Q4 Earnings Lag Estimates

ALAMEDA, Calif., Feb. 22, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Penumbra, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Penumbra (PEN) Q4 Earnings Expected to Decline

ALAMEDA, Calif., Feb. 10, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at Citi's 2022 Virtual Healthcare Conference on Thursday, February 24, 2022.

Penumbra, Inc. to Present at Citi's 2022 Virtual Healthcare Conference

ALAMEDA, Calif., Feb. 1, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2021 after market close on Tuesday, February 22, 2022 at 4:30 PM Eastern Time.

Penumbra, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 22, 2022

Shockwave Medical

Penumbra Inc (NYSE: PEN) is exploring a potential deal with Shockwave Medical Inc (NASDAQ: SWAV), Bloomberg reported citing people with knowledge of the matter. According to the people, Penumbra has held talks with Shockwave Medical about a potential tie-up.

Penumbra Weighing Combination With Shockwave Medical: Bloomberg

ALAMEDA, Calif., Dec. 22, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 40th Annual J.P.

News for Penumbra Stock (PEN)